Introduction
Recently, immunomodulation rather than simple immunosuppression has proven beneficial in the treatment of Multiple Sclerosis [1] [2] [3] [4] . Novel, effective immunomodulating agents such as fingolimod (FTY720) are expected to be launched in the near future. As far as published (ref) , efficacy and safety of fingolimod are very promising (ref) . To obtain long-term safety data, a close follow-up of patients treated with new immunomodulating agents and publication of newly detected relevant side effects and risks is warranted.
As a functional sphingosine 1-phosphate receptor antagonist, FTY720 inhibits lymphocyte emigration from lymphoid organs, thereby acting as an immunomodulator 5 . The results of clinical studies investigating FTY720 for the treatment of MS are promising 1 . The development of neoplasms has been discussed as a potential risk. Large phase II and III studies did not show a significant risk of the development of certain types of cancer during the time period of observation 1, 6 . However, the Phase II clinical study with FTY720 in MS showed a higher than expected rate of skin malignancies (basal cell carcinoma, squamous cell carcinoma and melanoma) 1, [7] [8] . As a consequence of such observations, annual dermatological full-skin examinations have been integrated into the clinical phase III trials for FTY720 in MS; however after recruitment was complete and therefore without baseline exam. The published data of the phase III TRANSFORMS trial for short-term application of FTY720 showed no melanoma in 420 patients on 1.25 mg FTY720, three melanomas in 429 patients on 0.5 mg FTY720, and no melanoma in 431 patients on interferon beta-1a. 9 . In the phase III FREEDOMS trial 10 with patients treated with FTY720 over 24 months, one melanoma in 429 patients on 1.25 mg FTY720, no melanoma in 425 patients on 0.5 mg FTY720, and one melanoma in 418 patients on placebo were noted. The only recently published 3-year results of a phase II study showed one patient with MM in the placebo/ FTY720 group after 25 months and one patient with MM <1 mm a sentinel lymph node biopsy was performed as an exception to routinely followed Swiss guidelines 12 . The sentinel lymph node showed a small intracapsular melanocytic naevus but no evidence of lymph node metastasis on histological examination.
Discussion

FTY720 is a functional sphingosine 1-phosphate receptor antagonist
Briefly, sphingosine-1-phosphate (S1P) as a lysophospholipid regulates numerous functions in intraand extracellular compartments. Best known are effects on the cardiovascular and the immune system. Five sphingosine 1-phosphate receptors are known (S1P 1 to S1P 5 ). Phosphorylated FTY720 binds and activates S1P 1 , S1P 3-5 , but not S1P 2
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. While FTY720 is an agonist at these four S1P
receptors, its binding leads to internalization and loss of receptor surface expression. FTY720
intriguingly ends up being a functional S1P antagonist with inhibition of lymphocyte egress from lymph nodes and secondary lymphoid tissues 14 . These properties have led to FTY720 being developed as a promising immunomodulatory drug in multiple sclerosis (MS) 1 .
Extended clinical trials provide new data on FTY720 in MS
The results from ongoing clinical MS trials are encouraging. However the continued use of FTY720
has been connected with a higher than expected rate of skin malignancies in the phase II study 8 . The reported short-term phase II data of continued treatment up to 36 months did not show a relevant elevation of this incidence 7, 10 . Our observed case of melanoma represents a melanoma occurring during extended treatment with FTY720 beyond the hitherto reported timeframe. While data on the role of S1P in melanoma formation is patchy, direct and indirect effects of S1P receptor modulation may matter for melanoma formation.
Direct effects of sphingosine 1-phosphate receptor modulation on melanoma
Sphingolipids have long been considered as rather passive structural components of cellular membranes. More recently, it has become evident that metabolism of sphingomyelin yields several lipid mediators that evoke diverse and specific responses in different cell types. The sphingomyelin derivate S1P has attracted particular attention in the interactions with malignant cells. S1P signalling has been linked with complex effects on several types of carcinoma cells via regulating migratory responses in epithelial tumours [15] [16] . Davaille et al. 17 suggested a concentration-dependent effect of S1P for survival and apoptosis in human hepatic myofibroblasts.
For melanocytes and melanoma cells, S1P exerts an influence which seems highly dependent on the receptor subtypes involved. S1P protects mouse melanocytes from UVB induced apoptosis by phosphorylation of both ERK and Akt and thus promotes survival 18 . The migration of B16 murine melanoma cells could be manipulated by S1P receptor subtype expression. Mainly, S1P 2 , for which FTY720 is not a ligand, downregulated cell motility and invasion, while agonism at S1P 1 and S1P 3 led to B16 migration 19 . Furthermore, S1P 2 activation inhibited melanoma metastasis formation in a murine model, while S1P 1 activation aggravated metastasis in this model 20 . The balance between ceramide and S1P expression was found to be critical for apoptosis susceptibility in human melanoma cell lines in culture 21 . Inhibition of angiogenesis and tumour vascularisation was shown for FTY720 with inhibited metastatic melanoma growth in a mouse model via decreased tumour cell proliferation and increased apoptosis 22 . S1P can also induce apoptosis in B16 melanoma cells apparently independent of S1P 1-3 receptors 23 . Due to its peculiar properties, FTY720 acts as an agonist of S1P receptors, but yields functional antagonism. ItsI impact on mechanisms involved in melanoma formation and progression remains elusive at this point in time. Association of MM and treatment with natalizumab was recently discussed controversially [26] [27] [28] . In a larger context, immunomodulation is under consideration to increase cancer incidence in several disease conditions [29] [30] [31] [32] Kommentar [GH1]: Ist aus meiner Sicht wichtig, würde ich lieber nicht weglassen. Müssen GH und ML besprechen.
Indirect effects of sphingosine 1-phosphate receptor modulation on melanoma
Melanoma
Conclusions
We describe a case of melanoma development during long-term treatment with FTY720. Causality is speculative. However, due to possible interactions between melanoma formation and progression with S1P and its receptor subtypes, FTY720 may be of functional relevance for melanoma formation.
Currently, it is not clear whether the higher than expected rate of skin malignancies in MS patients on FTY720 indeed exceeds the one in the general population. Ongoing clinical trials with FTY720 now include an annual dermatological whole-body skin examination. The incidence reported in the Phase III studies is based on active screening via dermatological exam and is therefore difficult to compare to historic cohorts.
A positive family history is a known risk factor for melanoma [33] [34] and should be weighed cautiously in the decision to start FTY720, while a personal history or the occurrence of melanoma should lead to cessation of FTY720 as done in our patient. Until further long-term data emerges to better assess the risk of skin-cancer development during treatment with FTY720, self-examinations of the skin every three months and a dermatological full-skin examination annually may be the best strategy regarding the currently unknown long-term risk of melanoma in FTY720-treated patients. Early removal of melanoma is the only curative treatment for this neoplasm to date. 
